Home Newsfeeds B of A Securities Downgrades Denbury to Underperform, Announces $71 Price Target

B of A Securities Downgrades Denbury to Underperform, Announces $71 Price Target

B of A Securities analyst Doug Leggate downgrades Denbury (NYSE:DEN) from Neutral to Underperform and announces $71 price target.

byBenzinga Newsdesk

July 19, 2022

1 minute read

B of A Securities analyst Doug Leggate downgrades Denbury (NYSE:DEN) from Neutral to Underperform and announces $71 price target.

News

Amwell Disclosed A Collaboration With Nestlé Health Science To Help Health Organizations Improve Patients’ Overall Health Through Innovative Digital Solutions Focused On Nutrition

By Benzinga Newsdesk

October 5, 7:06 AM

Amwell® (NYSE:AMWL), a leader in hybrid health care enablement, today announced a collaboration with Nestlé Health Science, a global leader in the science of nutrition, to help health organizations

AMWL

NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday

By Lisa Levin

June 30, 8:00 AM

Truist Securities boosted the price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $125 to $140. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. BioMarin Pharmaceutical shares fell 3.6% to close at $88.93 on Thursday.

ACCD

Bluejay Diagnostics, Inc. Announces Initiation Of Multicenter Clinical Study Evaluating Symphony IL-6 In Sepsis Patients

By Benzinga Newsdesk

December 27, 10:01 AM

This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives. ACTON, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics,

BJDX

Is Apple Vision Pro Durable? New Test Reveals If The $3500 Headset Can Withstand Bumps And Drops

By Ananya Gairola

February 5, 9:37 AM

Apple's Vision Pro mixed-reality headset proved to be more durable than it looks in various durability tests, withstanding impacts and drops remarkably well, suggesting its high price may reflect good value in build quality.

AAPL

B of A Securities Downgrades Denbury to Underperform, Announces $71 Price Target

Related Posts

Amwell Disclosed A Collaboration With Nestlé Health Science To Help Health Organizations Improve Patients’ Overall Health Through Innovative Digital Solutions Focused On Nutrition

NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday

Bluejay Diagnostics, Inc. Announces Initiation Of Multicenter Clinical Study Evaluating Symphony IL-6 In Sepsis Patients

Is Apple Vision Pro Durable? New Test Reveals If The $3500 Headset Can Withstand Bumps And Drops